Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 11:55 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1225–1248 of 7,061 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo- matched Clear all

Conditions: Schizophrenia
Interventions: APN1125, Placebo; Drug
Lead sponsor: CoMentis; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Glendale, California

Conditions: Healthy Volunteer, Atopic Dermatitis, Hidradenitis Suppurativa
Interventions: KT-474/Placebo, KT-474; Drug
Lead sponsor: Kymera Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 154 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 14
States / cities: Phoenix, Arizona • Sun City West, Arizona • Boynton Beach, Florida + 8 more

Conditions: Diabetes Mellitus, Type 2, Hypertension
Interventions: Placebo, BI 10773; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 825 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 35
States / cities: Huntsville, Alabama • Phoenix, Arizona • Lincoln, California + 29 more

Conditions: Hypercholesterolemia
Interventions: colesevelam HCl, placebo; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 8
States / cities: Washington D.C., District of Columbia • St Louis, Missouri • New Hyde Park, New York + 5 more

Conditions: Bipolar Disorder
Interventions: Ramelteon SL, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 642 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 138
States / cities: Birmingham, Alabama • Dothan, Alabama • Muscle Shoals, Alabama + 134 more

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: EXPD-101/FXS7553 Dose 1, EXPD-101/FXS7553 Dose 2, Placebo; Drug
Lead sponsor: Expedition Therapeutics, Inc; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 29
States / cities: Phoenix, Arizona • Encino, California • Northridge, California + 26 more

Conditions: Diabetes Mellitus, Type 2
Interventions: GSK1614235, Sitagliptin, Placebo; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 30 Years to 65 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 3
States / cities: Miami, Florida • Baton Rouge, Louisiana • Cincinnati, Ohio

Conditions: HIV, Endothelial Dysfunction, Oxidative Stress
Interventions: PharmaNAC (N-acetylcysteine), Matching placebo; Dietary Supplement
Lead sponsor: Indiana University; Other
Eligibility: 50 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Healthy Participants
Interventions: AZD3974, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 176 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Glendale, California • Baltimore, Maryland

Conditions: Lymphedema
Interventions: Ketoprofen, Placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 1
States / cities: Stanford, California

Conditions: Scabies
Interventions: Moxidectin Oral Product, Placebo; Drug
Lead sponsor: Medicines Development for Global Health; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 5
States / cities: Los Angeles, California • Miami, Florida • Tampa, Florida

Conditions: COVID-19, SARS-CoV-2 Infection, Coronavirus Infection
Interventions: TXA127, TRV027, Placebo, Fostamatinib; Drug
Lead sponsor: Sean Collins; Other
Eligibility: 18 Years and older
Enrollment: 1,060 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 51
States / cities: Birmingham, Alabama • Chandler, Arizona • Los Angeles, California + 40 more

Conditions: Constipation - Functional
Interventions: Lubiprostone, Placebo; Drug
Lead sponsor: Sucampo Pharma Americas, LLC; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 606 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 87
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 78 more

Conditions: Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)
Interventions: Dapagliflozin, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 4,744 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 86
States / cities: Fairhope, Alabama • Mobile, Alabama • Sheffield, Alabama + 74 more

Conditions: Ulcerative Colitis
Interventions: NX-13 250mg IR, NX-13 500mg IR, NX-13 500mg MR, Placebo; Drug
Lead sponsor: Landos Biopharma Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 22
States / cities: Huntsville, Alabama • Lancaster, California • Mission Viejo, California + 18 more

Conditions: Healthy
Interventions: Branched Chain Amino Acids, Placebo; Dietary Supplement · Other
Lead sponsor: Montana State University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Bozeman, Montana

Conditions: Pediatric Pyruvate Kinase Deficiency, Pediatric Hemolytic Anemia
Interventions: Mitapivat, Mitapivat-matching placebo; Drug
Lead sponsor: Agios Pharmaceuticals, Inc.; Industry
Eligibility: 1 Year to 17 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 9
States / cities: Phoenix, Arizona • Palo Alto, California • Atlanta, Georgia + 6 more

Conditions: Post-bariatric Hypoglycemia
Interventions: glucagon, Closed loop glucagon pump; Drug · Device
Lead sponsor: Joslin Diabetes Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Fatty Liver
Interventions: fenofibrate, pioglitazone, placebo; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 80 Years
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2014
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Multiple Sclerosis, Primary Progressive
Interventions: Ocrelizumab, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1,013 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 8
States / cities: Washington D.C., District of Columbia • Clearwater, Florida • Orlando, Florida + 5 more

Conditions: Lung Cancer
Interventions: Pembrolizumab, Epacadostat, Platinum-based chemotherapy, Placebo; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 21
States / cities: Daphne, Alabama • Goodyear, Arizona • Tucson, Arizona + 18 more

Conditions: Asthma Patients
Interventions: AZD1981, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 1,144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 19
States / cities: Fullerton, California • Los Angeles, California • Mission Viejo, California + 16 more

Conditions: Optic Neuritis
Interventions: Atacicept, Placebo matched to atacicept; Drug
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 8
States / cities: Birmingham, Alabama • Aurora, Colorado • Fairfield, Connecticut + 5 more

Conditions: Arthroplasty, Replacement, Knee
Interventions: JNJ-70033093 25 mg, JNJ-70033093 50 mg, JNJ-70033093 100 mg, JNJ-70033093 200 mg, Placebo, Enoxaparin 40 mg; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 50 Years and older
Enrollment: 1,242 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 9
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 6 more

Search by objective public record fields.

Safety, Tolerability, and Pharmacokinetics of Single Doses of APN1125 in Healthy Normal Subjects

A Single and Multiple Ascending Dose Trial of KT-474 in Healthy Adult Volunteers and Patients With Atopic Dermatitis (AD) or Hidradenitis Suppurativa (HS)

12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus

Efficacy and Safety of Colesevelam in Pediatric Patients With Genetic High Cholesterol

Efficacy and Safety of Ramelteon Sublingual as Adjunctive Therapy for Maintenance Treatment of Bipolar I Disorder

To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment

A 2-Part Trial in Subjects With Type 2 Diabetes and in Healthy Subjects to Evaluate GSK1614235, a New Glucose Lowering Drug to Treat Type 2 Diabetes

N-acetylcysteine to Reduce Oxidative Stress and Improve Endothelial Function in HIV-infected Older Adults

A Study to Investigate Safety, Tolerability, and Pharmacokinetics of AZD3974 in Healthy Participants

Lymphedema Study for Arm or Leg Lymphedema

Efficacy and Safety Study of Moxidectin in Adults With Scabies

Novel Experimental COVID-19 Therapies Affecting Host Response

Lubiprostone in Children With Functional Constipation

Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure

Safety, Tolerability, and Pharmacokinetics of Oral NX-13 in Active Ulcerative Colitis

Metabolomic Impacts of Branched-chain Amino Acid Supplementation During Endurance Exercise

A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Regularly Transfused, Followed by a 5-Year Extension Period

Closed-Loop Glucagon Pump for Treatment of Post-Bariatric Hypoglycemia

Insulin Resistance in Non-alcoholic Fatty Liver Disease

A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis

A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06)

Investigation of Efficacy, Safety and Tolerability of Once and Twice Daily Doses of AZD1981 in Asthmatic Patients

Atacicept in Subjects With Optic Neuritis

A Study of JNJ-70033093 (BMS-986177) Versus Subcutaneous Enoxaparin in Participants Undergoing Elective Total Knee Replacement Surgery